Re-engineering proteins to develop novel immunotherapies
European Pharmaceutical Review
JULY 13, 2023
By re-engineering existing approaches that have already shown clinical promise, there is potential to bring further benefit to the patient community in its fight against cancer. Since then, several next-generation antibodies have been engineered with modifications that enable them to better engage with immune cells.
Let's personalize your content